stockportfolio.pro
Supernus Pharmaceuticals, Inc. (SUPN)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGM
Supernus Pharmaceuticals, Inc. revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $215.00M | $302.24M | $408.90M | $392.75M | $520.40M | $579.77M | $667.24M | $607.52M | $661.82M | $718.95M |
| Gross profit | $203.02M | $287.02M | $393.54M | $376.10M | $467.94M | — | $580.02M | $523.74M | $583.91M | $644.39M |
| Net income | $91.22M | $57.28M | $110.99M | $113.06M | $126.95M | $53.42M | $60.71M | $1.32M | $73.86M | $-38.55M |
| Net margin | 42.4% | 19.0% | 27.1% | 28.8% | 24.4% | 9.2% | 9.1% | 0.2% | 11.2% | -5.4% |
Source: Supernus Pharmaceuticals, Inc. SEC filings (10-K). 16 years of history available in the interactive view.
Explore 16 years of Supernus Pharmaceuticals, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track SUPN in your portfolio →
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. It offers Qelbree, a non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD); GOCOVRI for the treatment of dyskinesia and levodopa/carbidopa in patients with Parkinson's Disease (PD); Oxtellar XR, an extended-release oxcarbazepine product indicated for the monotherapy treatment of partial onset epilepsy seizures; and APOKYN for the acute and intermittent treatment of hypomobility or off episodes in patients with advanced PD. It also provides Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; XADAGO for the treatment of levodopa/carbidopa in patients with PD experiencing off episodes; and MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and chronic sialorrhea. In addition, the company develops ONAPGO, which received FDA approval, for the treatment of motor fluctuations in adults with advanced PD; SPN-817, a first-in-class selective acetylcholinesterase inhibitor, which is in Phase 2 clinical trial, for the treatment of epilepsy, partial seizures, Dravet syndrome, and Lennox-Gaustaut syndrome; SPN-820, a small molecule in Phase 2 clinical trial for treating resistant depression; and SPN-443, a stimulant in Phase 1 trial for the treatment of ADHD/CNS. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. It has a development agreement with Navitor Inc. for the conduct of Phase 2 clinical program of SPN-820. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is based in Rockville, Maryland.
Supernus Pharmaceuticals, Inc. — frequently asked questions
What is Supernus Pharmaceuticals, Inc.'s revenue?
Supernus Pharmaceuticals, Inc. (SUPN) reported revenue of $718.95M for fiscal year 2025, up 8.6% from the prior year, according to its SEC filings.
Is Supernus Pharmaceuticals, Inc. profitable?
No — SUPN reported a net loss of $-38.55M in fiscal 2025.
What is SUPN's P/E ratio?
Supernus Pharmaceuticals, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is Supernus Pharmaceuticals, Inc. growing?
SUPN's revenue grew at roughly 6.7% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Supernus Pharmaceuticals, Inc.'s official SEC filings (10-K and 10-Q), covering 16 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.